MIDDLETON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has ...
Researchers describe an experimental approach to wound healing that could take advantage of silver's anti-bacterial properties, while sidestepping the damage silver can cause to cells needed for ...
Investigational Device Exemption (IDE) enables Imbed’s Silver-Gallium, Ultra-Thin Matrix Technology to be tested in human clinical studies, a key step towards marketing approval Fully synthetic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results